Patents by Inventor Leland J. Chinn

Leland J. Chinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5162365
    Abstract: This invention encompasses compounds and methods for inhibiting lipoxygenase and includes a pharmaceutical composition comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein the substituents are defined below. The compounds and pharmaceutical formulations of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.
    Type: Grant
    Filed: May 10, 1991
    Date of Patent: November 10, 1992
    Assignee: G. D. Searle & Co.
    Inventors: Leland J. Chinn, Bipinchandra N. Desai, Richard A. Mueller
  • Patent number: 5036105
    Abstract: This invention encompasses compounds and methods for inhibiting lipoxygenase and includes a pharmaceutical composition comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different members of the group consisting of tert-alkyl of 4 to 10 carbon atoms; and R.sub.3 isa) ##STR2## wherein R.sub.4 is hydrogen or lower alkyl; b) ##STR3## c) ##STR4## wherein R.sub.6 and R.sub.7 may be the same or different and are alkyl of 1 to 4 carbon atoms; ord) ##STR5## and the pharmaceutically acceptable salts thereof. The compounds and pharmaceutical formulations of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.
    Type: Grant
    Filed: October 14, 1988
    Date of Patent: July 30, 1991
    Assignee: G. D. Searle & Co.
    Inventors: Leland J. Chinn, Bipinchandra N. Desai, Richard A. Mueller
  • Patent number: 4801611
    Abstract: This invention encompasses compounds and methods for inhibiting lipoxygenase and includes a pharmaceutical composition comprising a pharmaceutical carrier and an effective lipoxygenase inhibiting amount of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different members of the group consisting of tert-alkyl of 4 to 10 carbon atoms; and R.sub.3 is ##STR2## wherein R.sub.4 is hydrogen or lower alkyl; ##STR3## wherein R.sub.6 and R.sub.7 may be the same or different and are alkyl of 1 to 4 carbon atoms; or ##STR4## and the pharmaceuticlaly acceptable salts thereof. The compounds and pharmaceutical formulations of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.
    Type: Grant
    Filed: May 7, 1987
    Date of Patent: January 31, 1989
    Assignee: G. D. Searle & Co.
    Inventors: Leland J. Chinn, Bipinchandra N. Desai, Richard A. Mueller
  • Patent number: 4694018
    Abstract: The compounds of the present invention comprise substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives thereof represented by the formula: ##STR1## wherein: R represents hydroxy, alkoxy of from 1 to 6 carbon atoms, inclusive, or amino; R.sup.1 represents hydrogen or acyl of from 2 to 7 carbon atoms, inclusive; and X represents hydrogen, halogen, hydroxy or alkoxy of from 1 to 6 carbon atoms, inclusive. The compounds of the present invention are 5-lipoxygenase inhibitors and, therefore, are useful in the treatment of local and systemic inflammation, allergy and hypersensitivity reactions and other disorders in which agents formed in the 5-lipoxygenase metabolic pathway are involved.
    Type: Grant
    Filed: November 29, 1985
    Date of Patent: September 15, 1987
    Assignee: G. D. Serale & Co.
    Inventor: Leland J. Chinn
  • Patent number: 4687864
    Abstract: The present invention describes 5-fluoro-3-oxaprostacyclin (PGI.sub.2) derivatives of Formula I. These compounds are useful for the treatment of platelet dysfunction, atherosclerosis, hypertension and tumor cell metastasis. Also disclosed is the process for preparing them and the appropriate intermediates. ##STR1## wherein R.sup.1 is: (a) Na, K, or 1/2 Ca, or other pharmaceutically acceptable cation(b) NR.sup.3 .sub.2 with the adjacent connecting oxygen omitted, where R.sup.3 =H, methyl, ethyl, isopropyl or a combination of these groups;(c) Alkyl of 1 to 6 carbon atoms, either branched or straight chain(d) Hydrogenwherein OH on carbon 15 is optionally on carbon 16;wherein X=OCH.sub.3 or OC.sub.2 H.sub.5 when neither C.sub.5 -C.sub.6 or C.sub.6 -C.sub.7 is a double bond and nothing if C.sub.5 -C.sub.6 or C.sub.6 -C.sub.7 is a double bond;wherein R.sup.
    Type: Grant
    Filed: September 18, 1985
    Date of Patent: August 18, 1987
    Assignee: G. D. Searle & Co.
    Inventors: Stevan W. Djuric, Leland J. Chinn, Kurt J. Rorig
  • Patent number: 4579958
    Abstract: The present invention describes 5-fluoro-3-oxa-prostacyclin (PGI.sub.2) derivatives of Formula I. These compounds are useful for the treatment of platelet dysfunction, atherosclerosis, hypertension and tumor cell metastasis. Also disclosed is the process for preparing them and the appropriate intermediates. ##STR1## wherein R.sup.1 is: (a) Na, K, or 1/2 Ca, or other pharmaceutically acceptable cation(b) NR.sup.3.sub.2, where R.sup.3 .dbd.H, methyl, ethyl, isopropyl or a combination of these groups;(c) Alkyl of 1 to 6 carbon atoms, either branched or straight chain(d) Hydrogenwherein OH on carbon 15 is optionally on carbon 16; wherein X.dbd.H, OCH.sub.3 or OC.sub.2 H.sub.5 when neither C.sub.5 -C.sub.6 or C.sub.6 -C.sub.7 is a double bond and nothing if C.sub.5 -C.sub.6 or C.sub.6 -C.sub.7 is a double bond;wherein R.sup.
    Type: Grant
    Filed: December 23, 1983
    Date of Patent: April 1, 1986
    Assignee: G. D. Searle & Co.
    Inventors: Stevan W. Djuric, Leland J. Chinn, Kurt J. Rorig
  • Patent number: 4459235
    Abstract: The invention relates to novel 2-cyanosteroids of Formula I which are useful for the induction of menses and the termination of pregnancy.
    Type: Grant
    Filed: March 3, 1983
    Date of Patent: July 10, 1984
    Assignee: G. D. Searle & Co.
    Inventors: Leland J. Chinn, Karlene W. Salamon
  • Patent number: 4388311
    Abstract: The invention relates to a method for the induction of menses or the termination of pregnancy by administration of a compound of Formula IV.
    Type: Grant
    Filed: May 6, 1982
    Date of Patent: June 14, 1983
    Assignee: G. D. Searle & Co.
    Inventor: Leland J. Chinn
  • Patent number: 4349474
    Abstract: The invention relates to novel 2-cyanosteroids of Formula I which are useful for the induction of menses and the termination of pregnancy.
    Type: Grant
    Filed: July 27, 1981
    Date of Patent: September 14, 1982
    Assignee: G. D. Searle & Co.
    Inventor: Leland J. Chinn
  • Patent number: 4010169
    Abstract: Preparation and the antilipogenic utility of (E)-4-hydroxy-11,15-dioxoprosta-8(12),13-dien-1-oic acid .gamma.-lactones are disclosed.
    Type: Grant
    Filed: March 10, 1976
    Date of Patent: March 1, 1977
    Assignee: G. D. Searle & Co.
    Inventors: Leland J. Chinn, Karlene W. Salamon
  • Patent number: 3954844
    Abstract: Preparation and the antispasmodic utility of (5Z,13E,15S)-15-hydroxy-11-oxoprosta-5,9,13-trien-1-oic acid and esters are disclosed.
    Type: Grant
    Filed: January 3, 1975
    Date of Patent: May 4, 1976
    Assignee: G. D. Searle & Co.
    Inventors: Frank B. Colton, Leland J. Chinn